Compare GEO & SNDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GEO | SNDX |
|---|---|---|
| Founded | 1984 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Homebuilding | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.2B | 1.8B |
| IPO Year | 1994 | 2016 |
| Metric | GEO | SNDX |
|---|---|---|
| Price | $15.43 | $20.05 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 13 |
| Target Price | $41.00 | ★ $80.23 |
| AVG Volume (30 Days) | ★ 1.7M | 1.2M |
| Earning Date | 02-12-2026 | 03-02-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 515.49 | N/A |
| EPS | ★ 1.69 | N/A |
| Revenue | ★ $2,531,574,000.00 | $111,304,000.00 |
| Revenue This Year | $7.93 | $617.40 |
| Revenue Next Year | $15.02 | $115.70 |
| P/E Ratio | $9.29 | ★ N/A |
| Revenue Growth | 4.43 | ★ 595.65 |
| 52 Week Low | $14.27 | $8.58 |
| 52 Week High | $32.09 | $22.73 |
| Indicator | GEO | SNDX |
|---|---|---|
| Relative Strength Index (RSI) | 36.66 | 45.71 |
| Support Level | $15.42 | $19.99 |
| Resistance Level | $16.57 | $21.89 |
| Average True Range (ATR) | 0.71 | 1.07 |
| MACD | -0.24 | -0.11 |
| Stochastic Oscillator | 3.85 | 16.18 |
The GEO Group Inc specializes in detention facilities and community reentry centers. It operates in four segments: U.S. Secure Services, which mainly encompasses U.S.-based secure services business; Electronic Monitoring and Supervision Services, which conducts its services in the United States, represents services provided to adults for monitoring services and evidence-based supervision and treatment programs for community-based parolees, probationers, and pretrial defendants; Reentry Services conducts its services in the United States represents services provided to adults for residential and non-residential treatment, educational and community-based programs, pre-release and half-way house programs; and International Services.
Syndax Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. Its product candidates include revumenib and axatilimab. It is developing revumenib, a selective menin-MLL inhibitor for KMT2A-rearranged (MLL-r) and NPM1-mutant acute leukemias, including ALL and AML. It is also developing axatilimab, a CSF-1R-blocking antibody for cGVHD and idiopathic pulmonary fibrosis. Entinostat is its oral, small molecule product candidate that has direct effects on both cancer cells and immune regulatory cells. The business activity of the group is functioned through the region of the United States.